<DOC>
	<DOC>NCT00718887</DOC>
	<brief_summary>Switching to Entecavir will result in superior antiviral efficacy as compared to continuing with Adefovir in patients with a suboptimal response to Adefovir</brief_summary>
	<brief_title>Suboptimal Responders to Adefovir Switching to Entecavir</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Chronic infection with hepatitis B virus (HBV)(detectable hepatitis B surface antibody (HBsAg) at screening and at least 24 weeks prior to screening, or detectable HBsAg for &lt;24 weeks and negative for immunoglobulin M core antibody) Documentation of hepatitis B e antigen (HBeAg) positive or negative status Naive to nucleoside/nucleotide analogues, with the exception of adefovir Suboptimal response to adefovir treatment No lamivudine/telbivudine, entecavir, or adefovir resistanceassociated substitutions at screening Male or female gender, aged 16 years and older Compensated liver function Serum alanine aminotransferase level &lt;10*upper limit of normal at screening Women who are pregnant or breastfeeding Evidence of decompensated cirrhosis Coinfection with HIV, hepatitis C virus, or hepatitis D virus Recent history of pancreatitis (within 24 weeks prior to the first dose of study medication) Chronic renal insufficiency, defined as a creatinine clearance &lt;50 mL/min Current abuse of illegal drugs or alcohol, sufficient in the investigator's opinion to prevent adequate compliance with study therapy or to increase the risk of hepatotoxicity or pancreatitis Other serious medical conditions that might preclude completion of this study or that require chronic administration of prohibited medications Serum creatinine level &gt;1.5 mg/dL; hemoglobin level &lt;10.0 g/dL; platelet count &lt;70,000/mm^3; absolute neutrophil count &lt;1500 cells/mm^3; serum alpha fetoprotein level &gt;100 ng/mL Except adefovir, any prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B (eg, lamivudine, entecavir), or any other experimental antiHBV antiviral, or any China Traditional Medicine Therapy with interferon, thymosin alpha, or other immunostimulators within 24 weeks of randomization Required chronic administration of medications that cause immunosuppression, that are associated with a high risk of nephrotoxicity or hepatotoxicity, or that affect renal excretion.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>